Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives

被引:39
作者
Atallah-Yunes, Suheil Albert [1 ]
Robertson, Michael J. [1 ]
机构
[1] Indiana Univ Sch Med, Dept Hematol & Med Oncol, Indianapolis, IN 46202 USA
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
cytokines; immunotherapy; interleukins; cancer; lymphoma; RECOMBINANT HUMAN INTERLEUKIN-12; NON-HODGKINS-LYMPHOMA; NATURAL-KILLER-CELLS; ALPHA-2 INTERFERON THERAPY; IN-VIVO; PHASE-I; DOSE-ESCALATION; NK CELLS; COMBINATION; RITUXIMAB;
D O I
10.3389/fimmu.2022.872010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cytokines regulate both the innate and adaptive immune responses to cancer. Although antitumor activity has been seen for several cytokines in preclinical models, they have had limited success as single therapeutic agents in clinical trials of cancer immunotherapy. However, the possible combinations of cytokines with other immune therapeutics and the advancement in genetic engineering, synthetic biology and cellular and immune therapy has led to the revival of interest in cytokines as anticancer agents. This article will review several immunostimulatory cytokines with anticancer activity, focusing on the those that have been studied in treatment of lymphoma and highlighting recent advances of potential clinical relevance.
引用
收藏
页数:10
相关论文
共 104 条
  • [1] SPONTANEOUS PRODUCTION OF ALPHA-INTERFERON AND BETA-INTERFERON IN HUMAN-LYMPHOBLASTOID AND LYMPHOMA CELL-LINES
    ADOLF, GR
    HAAS, OA
    FISCHER, P
    SWETLY, P
    [J]. ARCHIVES OF VIROLOGY, 1982, 72 (03) : 169 - 178
  • [2] Amer Magid H, 2014, Mol Cell Ther, V2, P27
  • [3] A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12
    Angiolillo, AL
    Sgadari, C
    Tosato, G
    [J]. INERLEUKIN 12: CELLULAR AND MOLECULAR IMMUNOLOGY OF AN IMPORTANT REGULATORY CYTOKINE, 1996, 795 : 158 - 167
  • [4] Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    Ansell, SM
    Witzig, TE
    Kurtin, PJ
    Sloan, JA
    Jelinek, DF
    Howell, KG
    Markovic, SN
    Habermann, TM
    Klee, GG
    Atherton, PJ
    Erlichman, C
    [J]. BLOOD, 2002, 99 (01) : 67 - 74
  • [5] Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients
    Ansell, Stephen M.
    Geyer, Susan M.
    Maurer, Matthew J.
    Kurtin, Paul J.
    Micallef, Ivana N. M.
    Stella, Philip
    Etzell, Paul
    Novak, Anne J.
    Erlichman, Charles
    Witzig, Thomas E.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6056 - 6063
  • [6] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
    Atkins, MB
    Lotze, MT
    Dutcher, JP
    Fisher, RI
    Weiss, G
    Margolin, K
    Abrams, J
    Sznol, M
    Parkinson, D
    Hawkins, M
    Paradise, C
    Kunkel, L
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2105 - 2116
  • [7] Atkins MB, 1997, CLIN CANCER RES, V3, P409
  • [8] Allogeneic natural killer cells for refractory lymphoma
    Bachanova, Veronika
    Burns, Linda J.
    McKenna, David H.
    Curtsinger, Julie
    Panoskaltsis-Mortari, Angela
    Lindgren, Bruce R.
    Cooley, Sarah
    Weisdorf, Daniel
    Miller, Jeffrey S.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (11) : 1739 - 1744
  • [9] Bajetta E, 1998, CLIN CANCER RES, V4, P75
  • [10] IL-21 Contributes to JAK3/STAT3 Activation and Promotes Cell Growth in ALK-Positive Anaplastic Large Cell Lymphoma
    Bard, Jennifer Dien
    Gelebart, Pascal
    Anand, Mona
    Zak, Zoulika
    Hegazy, Samar A.
    Amin, Hesham M.
    Lai, Raymond
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2009, 175 (02) : 825 - 834